Chief R&D Officer Zalevsky Jonathan sold $13,388 worth of shares (186 units at $71.98), decreasing direct ownership by 2% to 9,570 units (SEC Form 4) (withholding obligation)

ByQuantisnow·Wall Street's wire, on your screen.

NKTR· Nektar Therapeutics

Health Care

Original source

Chief R&D Officer Zalevsky Jonathan sold $13,388 worth of shares (186 units at $71.98), decreasing direct ownership by 2% to 9,570 units (SEC Form 4) (withholding obligation) | Quantisnow